Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson's disease brain.


Journal

Molecular neurodegeneration
ISSN: 1750-1326
Titre abrégé: Mol Neurodegener
Pays: England
ID NLM: 101266600

Informations de publication

Date de publication:
05 05 2021
Historique:
received: 09 10 2020
accepted: 14 04 2021
entrez: 5 5 2021
pubmed: 6 5 2021
medline: 16 12 2021
Statut: epublish

Résumé

Parkinson's disease (PD) is a complex, age-related neurodegenerative disorder of largely unknown etiology. PD is strongly associated with mitochondrial respiratory dysfunction, which can lead to epigenetic dysregulation and specifically altered histone acetylation. Nevertheless, and despite the emerging role of epigenetics in age-related brain disorders, the question of whether aberrant histone acetylation is involved in PD remains unresolved. We studied fresh-frozen brain tissue from two independent cohorts of individuals with idiopathic PD (n = 28) and neurologically healthy controls (n = 21). We performed comprehensive immunoblotting to identify histone sites with altered acetylation levels in PD, followed by chromatin immunoprecipitation sequencing (ChIP-seq). RNA sequencing data from the same individuals was used to assess the impact of altered histone acetylation on gene expression. Immunoblotting analyses revealed increased acetylation at several histone sites in PD, with the most prominent change observed for H3K27, a marker of active promoters and enhancers. ChIP-seq analysis further indicated that H3K27 hyperacetylation in the PD brain is a genome-wide phenomenon with a strong predilection for genes implicated in the disease, including SNCA, PARK7, PRKN and MAPT. Integration of the ChIP-seq with transcriptomic data from the same individuals revealed that the correlation between promoter H3K27 acetylation and gene expression is attenuated in PD patients, suggesting that H3K27 acetylation may be decoupled from transcription in the PD brain. Strikingly, this decoupling was most pronounced among nuclear-encoded mitochondrial genes, corroborating the notion that impaired crosstalk between the nucleus and mitochondria is involved in the pathogenesis of PD. Our findings independently replicated in the two cohorts. Our findings strongly suggest that aberrant histone acetylation and altered transcriptional regulation are involved in the pathophysiology of PD. We demonstrate that PD-associated genes are particularly prone to epigenetic dysregulation and identify novel epigenetic signatures associated with the disease.

Sections du résumé

BACKGROUND
Parkinson's disease (PD) is a complex, age-related neurodegenerative disorder of largely unknown etiology. PD is strongly associated with mitochondrial respiratory dysfunction, which can lead to epigenetic dysregulation and specifically altered histone acetylation. Nevertheless, and despite the emerging role of epigenetics in age-related brain disorders, the question of whether aberrant histone acetylation is involved in PD remains unresolved.
METHODS
We studied fresh-frozen brain tissue from two independent cohorts of individuals with idiopathic PD (n = 28) and neurologically healthy controls (n = 21). We performed comprehensive immunoblotting to identify histone sites with altered acetylation levels in PD, followed by chromatin immunoprecipitation sequencing (ChIP-seq). RNA sequencing data from the same individuals was used to assess the impact of altered histone acetylation on gene expression.
RESULTS
Immunoblotting analyses revealed increased acetylation at several histone sites in PD, with the most prominent change observed for H3K27, a marker of active promoters and enhancers. ChIP-seq analysis further indicated that H3K27 hyperacetylation in the PD brain is a genome-wide phenomenon with a strong predilection for genes implicated in the disease, including SNCA, PARK7, PRKN and MAPT. Integration of the ChIP-seq with transcriptomic data from the same individuals revealed that the correlation between promoter H3K27 acetylation and gene expression is attenuated in PD patients, suggesting that H3K27 acetylation may be decoupled from transcription in the PD brain. Strikingly, this decoupling was most pronounced among nuclear-encoded mitochondrial genes, corroborating the notion that impaired crosstalk between the nucleus and mitochondria is involved in the pathogenesis of PD. Our findings independently replicated in the two cohorts.
CONCLUSIONS
Our findings strongly suggest that aberrant histone acetylation and altered transcriptional regulation are involved in the pathophysiology of PD. We demonstrate that PD-associated genes are particularly prone to epigenetic dysregulation and identify novel epigenetic signatures associated with the disease.

Identifiants

pubmed: 33947435
doi: 10.1186/s13024-021-00450-7
pii: 10.1186/s13024-021-00450-7
pmc: PMC8097820
doi:

Substances chimiques

Antiparkinson Agents 0
Histones 0
SIRT1 protein, human EC 3.5.1.-
SIRT2 protein, human EC 3.5.1.-
SIRT3 protein, human EC 3.5.1.-
Sirtuin 1 EC 3.5.1.-
Sirtuin 2 EC 3.5.1.-
Sirtuin 3 EC 3.5.1.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

31

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH110928
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH111721
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH103340
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH109956
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH105898
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH109677
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH117291
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH094714
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH117292
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH116492
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH103346
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH103877
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH110927
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH103365
Pays : United States
Organisme : NIMH NIH HHS
ID : P50 MH106934
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH116488
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH116489
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH110905
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH110920
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH117293
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH110921
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH116438
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH103392
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH103339
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH102791
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH105853
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH116441
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH109715
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH116487
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH110926
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH105881
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH116442
Pays : United States

Références

Science. 1997 Jun 27;276(5321):2045-7
pubmed: 9197268
Cell. 2016 Nov 17;167(5):1385-1397.e11
pubmed: 27863250
Genetics. 2018 Aug;209(4):1055-1071
pubmed: 29871881
Neurosci Lett. 2016 Aug 3;627:121-5
pubmed: 27241718
Nucleic Acids Res. 2016 Nov 16;44(20):e153
pubmed: 27484474
NPJ Aging Mech Dis. 2016 Aug 18;2:16017
pubmed: 28721271
PLoS Comput Biol. 2013;9(8):e1003118
pubmed: 23950696
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Cold Spring Harb Perspect Med. 2012 Aug 01;2(8):
pubmed: 22908195
Cell Metab. 2013 Aug 6;18(2):239-50
pubmed: 23931755
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21931-6
pubmed: 21106759
Acta Neuropathol Commun. 2020 Apr 21;8(1):55
pubmed: 32317022
Arch Neurol. 1999 Jan;56(1):33-9
pubmed: 9923759
Mov Disord. 2017 Nov;32(11):1504-1523
pubmed: 29124790
Nat Neurosci. 2008 Nov;11(11):1271-82
pubmed: 18849986
Cell Metab. 2015 Jul 7;22(1):31-53
pubmed: 26118927
Cell Death Differ. 2006 Apr;13(4):539-50
pubmed: 16167067
Nucleic Acids Res. 2013 Sep;41(17):8072-84
pubmed: 23821663
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):851-7
pubmed: 19246476
Mol Brain. 2017 Nov 28;10(1):53
pubmed: 29183391
BMC Bioinformatics. 2010 Apr 01;11:165
pubmed: 20356413
Biol Psychiatry. 2018 Dec 1;84(11):787-796
pubmed: 30177255
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
Trends Biochem Sci. 2016 Aug;41(8):700-711
pubmed: 27283514
Hum Mol Genet. 2017 Oct 1;26(R2):R216-R224
pubmed: 28977446
Front Neurosci. 2019 Mar 29;13:277
pubmed: 30983962
Nature. 2016 May 5;533(7601):95-9
pubmed: 27096366
Brain Res. 2010 Feb 26;1316:112-9
pubmed: 20036220
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2926-31
pubmed: 20133639
Lancet Neurol. 2019 Dec;18(12):1091-1102
pubmed: 31701892
Eur J Neurosci. 2006 Sep;24(5):1366-72
pubmed: 16987221
Am J Hum Genet. 2008 Jun;82(6):1375-84
pubmed: 18513678
Science. 2017 Sep 1;357(6354):891-898
pubmed: 28860381
Cancer Res. 2006 Feb 1;66(3):1277-81
pubmed: 16452179
Neuron. 2015 Jan 21;85(2):257-73
pubmed: 25611507
Stem Cell Reports. 2017 Dec 12;9(6):1839-1852
pubmed: 29129681
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Acta Neuropathol. 2018 Mar;135(3):409-425
pubmed: 29270838
Ann Neurol. 2017 Jun;81(6):898-903
pubmed: 28439961
Arch Neurol. 2001 Sep;58(9):1395-402
pubmed: 11559310
Lancet. 1989 Jun 3;1(8649):1269
pubmed: 2566813
Hum Mol Genet. 2017 Jan 1;26(1):226-232
pubmed: 28011712
Parkinsons Dis. 2017;2017:2643587
pubmed: 28634568
J Biol Chem. 2005 Mar 18;280(11):10264-76
pubmed: 15632193
eNeuro. 2017 Nov 30;4(6):
pubmed: 29204516
Mol Neurodegener. 2009 Feb 25;4:12
pubmed: 19243613
Cell Rep. 2018 Aug 14;24(7):1722-1729
pubmed: 30110629
Nucleic Acids Res. 2018 Jan 4;46(D1):D252-D259
pubmed: 29140464
Biochim Biophys Acta. 2010 Aug;1804(8):1591-603
pubmed: 20132909
PLoS One. 2011 Apr 26;6(4):e19194
pubmed: 21541336
Parkinsonism Relat Disord. 2018 Jan;46 Suppl 1:S30-S33
pubmed: 28780180
Mech Ageing Dev. 2010 Jan;131(1):21-8
pubmed: 19913571
Adv Neurol. 1990;53:245-9
pubmed: 2239463
Neurosci Lett. 2018 Feb 14;666:48-57
pubmed: 29273397
J Neurosci. 1996 Jul 15;16(14):4491-500
pubmed: 8699259
Cold Spring Harb Perspect Med. 2012 Jan;2(1):a008888
pubmed: 22315721
Neurology. 2000;54(11 Suppl 5):S21-3
pubmed: 10854357
Cell Death Differ. 2011 May;18(5):769-82
pubmed: 21113145
Nature. 2011 May 5;473(7345):43-9
pubmed: 21441907
Aging Cell. 2008 Jan;7(1):101-11
pubmed: 18031569
Bioinformatics. 2017 Aug 01;33(15):2381-2383
pubmed: 28369316
Nat Neurosci. 2018 Nov;21(11):1618-1627
pubmed: 30349106
J Comp Neurol. 2016 Dec 15;524(18):3865-3895
pubmed: 27187682
Mov Disord. 2018 Oct;33(10):1591-1600
pubmed: 30256453
Science. 2015 Dec 4;350(6265):1208-13
pubmed: 26785480
Neurobiol Aging. 2018 Apr;64:158.e1-158.e6
pubmed: 29290481
Nat Protoc. 2010 Jun;5(6):1148-59
pubmed: 20539290
J Neuropathol Exp Neurol. 2003 Aug;62(8):812-9
pubmed: 14503637
J Biol Chem. 2016 Feb 12;291(7):3531-40
pubmed: 26699403
Nat Neurosci. 2018 Apr;21(4):497-505
pubmed: 29507413
Biochim Biophys Acta Bioenerg. 2017 Dec;1858(12):991-998
pubmed: 28947253
Science. 2004 Oct 22;306(5696):636-40
pubmed: 15499007
Brain. 2013 Dec;136(Pt 12):3738-52
pubmed: 24136825
Brain. 1986 Oct;109 ( Pt 5):845-83
pubmed: 3779372
Nat Neurosci. 2018 Aug;21(8):1126-1136
pubmed: 30038276
Int J Mol Sci. 2017 Jul 10;18(7):
pubmed: 28698521
Genome Biol. 2017 Jan 30;18(1):22
pubmed: 28137300
Front Neurol. 2018 Mar 12;9:138
pubmed: 29593637
J Neurol. 2019 Nov;266(11):2605-2619
pubmed: 30377818
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W202-8
pubmed: 19458158
Neurobiol Dis. 2019 Apr;124:230-239
pubmed: 30448284
Nat Commun. 2018 Jan 2;9(1):12
pubmed: 29295991

Auteurs

Lilah Toker (L)

Neuro-SysMed Center of Excellence for Clinical Research in Neurological Diseases, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway.
Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway.

Gia T Tran (GT)

Neuro-SysMed Center of Excellence for Clinical Research in Neurological Diseases, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway.
Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway.

Janani Sundaresan (J)

Neuro-SysMed Center of Excellence for Clinical Research in Neurological Diseases, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway.
Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway.

Ole-Bjørn Tysnes (OB)

Neuro-SysMed Center of Excellence for Clinical Research in Neurological Diseases, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway.
Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway.

Guido Alves (G)

The Norwegian Centre for Movement Disorders and Department of Neurology, Stavanger University Hospital, Pb 8100, 4068, Stavanger, Norway.
Department of Mathematics and Natural Sciences, University of Stavanger, 4062, Stavanger, Norway.

Kristoffer Haugarvoll (K)

Neuro-SysMed Center of Excellence for Clinical Research in Neurological Diseases, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway.
Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway.

Gonzalo S Nido (GS)

Neuro-SysMed Center of Excellence for Clinical Research in Neurological Diseases, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway.
Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway.

Christian Dölle (C)

Neuro-SysMed Center of Excellence for Clinical Research in Neurological Diseases, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway.
Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway.

Charalampos Tzoulis (C)

Neuro-SysMed Center of Excellence for Clinical Research in Neurological Diseases, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway. charalampos.tzoulis@uib.no.
Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway. charalampos.tzoulis@uib.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH